Welcome to our dedicated page for Addex Therapeutics SEC filings (Ticker: ADXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company focused on small-molecule allosteric modulators. As a foreign issuer listed on the NASDAQ Capital Market, Addex Therapeutics reports to the SEC using forms such as Form 20-F for annual reports and Form 6-K for current information.
Recent Form 6-K filings for Addex Therapeutics include press releases, unaudited interim condensed consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations. These documents are often incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, as disclosed in the filings. The company’s reports also emphasize that its business faces significant risks and refer readers to risk factors discussed in its Form 20-F.
On Stock Titan, Addex Therapeutics filings are updated from the SEC’s EDGAR system, and AI-generated summaries can help explain the structure and key points of lengthy documents. Users can review annual disclosures on Form 20-F, interim information and press releases furnished on Form 6-K, and other registered offerings referenced in the company’s F-3 and S-8 statements.
For those analyzing ADXN, this filings page offers a structured view of Addex Therapeutics’ regulatory history, including financial statement presentations, discussions of results of operations, and risk disclosures that the company highlights as important to understanding its business and prospects.
Addex Therapeutics furnished a report highlighting progress at its spin-out company Neurosterix, which has started a Phase 1 clinical study of NTX-253, an oral positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia. The first-in-human trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Neurosterix was spun out of Addex in April 2024 and raised $65 million in a Series A financing led by funds affiliated with Perceptive Advisors; Addex retains a 20% equity interest in the company. The filing also reiterates Addex’s broader neurology-focused pipeline, including lead candidate dipraglurant for brain injury recovery, partnered and independent GABAB PAM programs for substance use disorders and chronic cough, and its investments in Neurosterix and Stalicla.
Addex Therapeutics Ltd has filed a shelf registration on Form F-3 to offer up to $150,000,000 of ordinary shares, which may be issued directly or as American Depositary Shares, each ADS representing 120 ordinary shares. The securities may be sold over time in one or more primary offerings using various methods, including underwriters, dealers, agents or direct sales, with specific terms to be detailed in future prospectus supplements.
The ADSs trade on Nasdaq under “ADXN” and the shares trade on SIX under “ADXN.” As of November 17, 2025, the ADS price on Nasdaq was $8.47, and the SIX share price was CHF 0.0572 (approximately $0.072 per share, or about $8.64 per ADS). Under Form F-3 General Instruction I.B.5, Addex may not sell more than one‑third of its $9.05 million public float in primary offerings in any 12‑month period.
Addex Therapeutics (ADXN) furnished a Form 6-K noting it issued a press release on October 29, 2025, attached as Exhibit 99.1 and incorporated by reference.
The press release is deemed part of Addex’s registration statements on Form F-3 (No. 333-255089) and Form S-8 (Nos. 333-255124 and 333-272515) from the filing date, unless later superseded.
Addex Therapeutics (ADXN) filed a Form 6-K reporting the incorporation of a press release dated June 25, 2025 into their SEC filings. The press release will be incorporated by reference into two existing registration statements:
- Form F-3 (Registration No. 333-255089)
- Form S-8 (Registration Numbers 333-255124 and 333-272515)
The document was signed by Tim Dyer, Chief Executive Officer. While the filing mentions the press release as Exhibit 99.1, the actual content of the press release is not included in this filing. This is a routine foreign issuer filing that serves primarily to incorporate the referenced press release into the company's existing registration statements.
Schedule 13D/A (Amendment 8) – Addex Therapeutics Ltd (ADXN)
The filing, triggered on 20 June 2025, discloses the current beneficial ownership position of Chief Executive Officer Timothy Mark Dyer in Addex Therapeutics Ltd. Dyer reports ownership or control over 18,208,437 ordinary shares, equal to 12.94 % of the company’s 139,391,883 outstanding ordinary shares as last reported in the Form 6-K filed on 20 June 2025.
Key ownership figures:
- Sole voting and dispositive power: 18,208,437 shares
- Shared voting/dispositive power: 0 shares
- Breakdown: 16,848,979 ordinary shares held outright and 1,359,458 shares issuable upon exercise of options that are exercisable within 60 days of 20 June 2025.
The filing details the history of share acquisitions and option grants from 2007 through 2025, including purchases with personal funds in various private placements (e.g., 36,364 shares at CHF 2.75 on 9 Aug 2013) and numerous option grants that were largely exercised on 26 Oct 2022 at a deferred strike price of CHF 0.13 per share. Dyer has also regularly received ordinary-share compensation in his capacity as CEO.
No criminal or civil proceedings are disclosed against the reporting person, and the source of funds for all cash purchases was personal funds (“PF, OO”). The filing reports citizenship in both Switzerland and the United Kingdom.
For investors, the amendment confirms that the company’s chief executive maintains a double-digit equity stake, signalling strong insider alignment but does not indicate any new purchase or sale since the prior amendment. No additional financing, earnings, or strategic transactions are discussed in this document.
Addex Therapeutics Ltd (ADXN) filed a routine Form 6-K on 20 June 2025. The filing primarily serves two administrative purposes: (1) it makes available unaudited interim condensed consolidated financial statements, management’s discussion and analysis (MD&A), and a 19 June 2025 press release as Exhibits 99.1-99.3; and (2) it formally incorporates those exhibits by reference into the company’s existing shelf registration statement on Form F-3 (No. 333-255089) and employee share-plan registration statements on Form S-8 (Nos. 333-255124 and 333-272515).
The company re-iterates that investors should review the risk factors detailed in its Form 20-F for the year ended 31 December 2024, filed 15 May 2025, and cautions that forward-looking statements remain subject to those risks. No new financial metrics, guidance, or transactional announcements are included in this 6-K.
CEO Tim Dyer signed the report on behalf of the registrant.
FAQ
What is the current stock price of Addex Therapeutics (ADXN)?
What is the market cap of Addex Therapeutics (ADXN)?
